Stage III NSCLC: Resectable vs Unresectable — The Decision That Defines Everything
Stage III NSCLC is the most heterogeneous group. Multidisciplinary decision-making is not optional — it is the standard. From N2a (now Stage IIB in 9th edition) to bulky N2b–N3 disease, treatment spans surgery, chemoradiation, targeted therapy, and immunotherapy in complex combinations.
Clinical Snapshot — Before Staging and Treatment Planning, Confirm:
- CT chest/abdomen/pelvis + PET-CT
- Pathologic mediastinal staging (EBUS/EUS if CT/PET suspicious nodes) — distinguish N2a (single station) vs N2b (multi-station)
- Pulmonary function tests (FEV1, DLCO)
- EGFR/ALK mutation status (mandatory — changes consolidation therapy)
- PD-L1 TPS (for IO consolidation eligibility)
- Brain MRI
- MDT discussion — surgery, radiation oncology, medical oncology
Microscopic Stage IIIA: Incidental N2 at Surgery
Section ID: microscopic-iiia
Your patient had surgery — unexpected N2 disease found on final pathology. What now?
Adjuvant Chemotherapy
- Incidental N2 (microscopic, single-station): adjuvant cisplatin-based chemotherapy ×4 cycles — proven OS benefit.
Adjuvant Immunotherapy (after chemotherapy)
Atezolizumab (IMpower010)
Stage II–IIIA, PD-L1 ≥1%
DFS HR 0.66 — FDA approved
Pembrolizumab (KEYNOTE-091)
Stage IB ≥4cm–IIIA, unselected PD-L1
DFS HR 0.76 — FDA approved
Both are FDA-approved. Choose based on PD-L1 result and local availability.
Driver-Positive Disease
- EGFR Ex19del/L858R: adjuvant osimertinib 3 years (ADAURA trial). Do not add IO — concurrent or sequential IO in EGFR+ is not indicated.
- ALK+: adjuvant alectinib 2 years (ALINA trial). Do not add IO.
PORT (Postoperative Radiotherapy)
PORT is no longer standard of care
Lung-ART trial: PORT did NOT improve OS (3yr OS 66.5% vs 68.5%) and increased cardiopulmonary toxicity. PORT is abandoned as standard after complete resection + adjuvant chemotherapy.
Lung-ART Trial — Full Data
Conclusion: PORT abandoned as standard after complete resection with adjuvant chemotherapy.
High-Risk Pathology: STAS and Core Features of Invasion
Section ID: high-risk-pathology
What histological features define high-risk resectable NSCLC — and how do they change management?
STAS — Spread Through Air Spaces
Definition: STAS refers to the spread of lung cancer cells into the air spaces beyond the edge of the main tumor — involving alveolar ducts, alveoli, or bronchioles. It is recognised as a histological feature of invasion by the 2021 WHO Classification of Thoracic Tumours and is present in approximately 20–38% of surgically resected NSCLC, predominantly in adenocarcinoma.
Clinical Significance of STAS
- STAS is an independent predictor of worse recurrence-free survival and overall survival after resection of early-stage NSCLC (especially adenocarcinoma).
- Associated with increased risk of locoregional recurrence, particularly after sublobar resection — STAS-positive tumors favor lobectomy over wedge/segmentectomy.
- Sub-lobar resection in STAS-positive cases carries a significantly higher recurrence rate vs lobectomy in retrospective data. Lobectomy is preferred when STAS is identified or suspected pre-operatively.
- STAS may influence adjuvant systemic therapy decision (consider adjuvant chemo for Stage IB with STAS given higher recurrence risk).
Core Morphological Features of Invasion
Visceral Pleural Invasion (VPI)
Upstages T1 to T2. Elastic stain confirmation required. Associated with worse prognosis and N1 node involvement.
Lymphovascular Invasion (LVI)
Vascular or lymphatic tumor emboli. Independent poor prognostic factor. May influence adjuvant chemo decision in Stage IB.
Perineural Invasion (PNI)
Less common. Associated with higher T stage and poorer outcomes. Consider in adjuvant therapy risk stratification.
Micropapillary / Solid Pattern
Adenocarcinoma subtypes with highest invasive potential. Micropapillary and solid predominant = higher risk of recurrence, nodal spread, and STAS co-occurrence.
Pathology Report Checklist for High-Risk Features
Adjuvant Radiotherapy (PORT) — Indications and Timing
Section ID: adjuvant-rt
After curative resection of Stage II–III NSCLC, when (if ever) is postoperative radiotherapy indicated?
PORT is not standard of care after R0 resection of pN2 disease
Remaining Indications for PORT
- R1 or R2 resection (microscopically or macroscopically positive margins): PORT is indicated, ideally concurrent or sequential with adjuvant chemotherapy. Re-resection should first be considered if feasible.
- Multidisciplinary review at a centre with thoracic radiation expertise before deciding on PORT in marginal cases.
PORT for Persistent N2 (yN2) After Peri-Operative Treatment
yN2 (persistent pathological N2 at surgical resection after neoadjuvant therapy): This scenario — where neoadjuvant chemo-IO achieves nodal downstaging in some patients but not all — creates a specific PORT question. Patients with yN2 disease are at high risk of locoregional recurrence despite systemic adjuvant continuation. In many centres, PORT is considered on an individual MDT basis, though its role is evolving and not yet validated prospectively in the chemo-IO era. No large RCT has established PORT benefit specifically in post-neoadjuvant-IO yN2 disease.
Timing for PORT
- When PORT is required (R1–R2), begin as soon as the patient has recovered from surgery and completed adjuvant chemotherapy — typically 4–6 weeks after completion of adjuvant chemotherapy.
- PORT dose typically 50–54Gy in 25–27 fractions. Ensure adequate lung sparing (MLD ≤20Gy, V20 ≤30%).
- Modern intensity-modulated RT (IMRT) or volumetric arc therapy (VMAT) should be used where available to reduce cardiac and pulmonary toxicity vs 3D-CRT.
Adjuvant Systemic Treatment Framework
Section ID: adjuvant-systemic
How do we decide between chemotherapy, targeted therapy, and immunotherapy after curative surgery?
Prognosis of Stage I–III After Curative Surgery
| Stage (8th Ed) | Approximate 5yr OS | Adjuvant Chemo Standard? |
|---|---|---|
| IA (T1a–c N0) | ≥80% | No |
| IB (T2a N0) | 68–73% | Consider if high-risk features (STAS, VPI, LVI) |
| IIA (T2b N0 / T1N1) | 53–60% | Yes — cisplatin doublet |
| IIB (T3N0 / T2N1) | 40–50% | Yes — cisplatin doublet |
| IIIA (T1-3 N2 / T4N0-1) | 25–35% | Yes — cisplatin doublet; consider peri-op IO |
| IIIB (T1-2 N3 / T3-4 N2b) | 10–25% | Individualised; often trimodality |
Adjuvant Chemo / Targeted / IO — Decision Tree
Step 1: Test for EGFR / ALK / other drivers
Molecular profiling is mandatory before adjuvant decision. EGFR and ALK status drives the entire adjuvant pathway.
EGFR Ex19del / L858R positive
→ Adjuvant osimertinib 80mg/day × 3 years (ADAURA). Adjuvant chemotherapy may be given first (optional); IO is contraindicated.
ALK-rearranged
→ Adjuvant alectinib 600mg BID × 2 years (ALINA). Chemotherapy may be omitted. IO is contraindicated.
Driver-negative (EGFR/ALK wild-type)
→ Adjuvant cisplatin-based chemotherapy × 4 cycles (Stage IIA–IIIA). Then consider adjuvant IO (atezolizumab if PD-L1 ≥1%; pembrolizumab unselected PD-L1, Stage IB≥4cm–IIIA).
Adjuvant Chemotherapy in the Elderly
Adjuvant cisplatin-based chemotherapy is associated with significant toxicity in patients ≥70 years. Evidence from LACE meta-analysis and ANITA trial suggest overall survival benefit is maintained in fit elderly patients (ECOG PS 0–1, no significant comorbidity). Use geriatric assessment tools (G8, CARG score) to stratify fitness. Carboplatin substitution for cisplatin reduces toxicity but may reduce efficacy — acceptable for frail elderly or cisplatin-ineligible patients.
Cisplatin Eligibility Criteria
- GFR ≥45–50 mL/min (cisplatin requires adequate renal function)
- ECOG PS 0–1 (cisplatin in PS 2 carries high toxicity risk)
- Adequate hearing (cisplatin ototoxicity) — formal audiometry if clinically uncertain
- No peripheral neuropathy Grade ≥2 (cisplatin neuropathy additive)
- If cisplatin-ineligible: substitute carboplatin AUC5–6. Preferred partner: vinorelbine (adenocarcinoma), gemcitabine (squamous), or pemetrexed (non-squamous, non-EGFR/ALK).
Timing of Adjuvant Chemo / Targeted / IO
EGFR+ Resectable Stage II–III: Adjuvant and Neoadjuvant Strategies
Section ID: egfr-resectable
EGFR Ex19del or L858R is confirmed after resection — or you are planning neoadjuvant treatment. What is the optimal strategy?
ADAURA: 3 Years Adjuvant Osimertinib
ADAURA — OS HR 0.49 (2023 update)
Adjuvant osimertinib for 3 years after resection of EGFR-mutated (Ex19del or L858R) Stage IB–IIIA NSCLC is associated with a 51% reduction in the risk of death compared to placebo. This represents a landmark OS benefit from an adjuvant targeted therapy in lung cancer.
ADAURA Trial — Full Data (ASCO 2023 OS Update)
Conclusion: Adjuvant osimertinib for 3 years = standard of care for EGFR-mutated resected Stage IB–IIIA NSCLC.
The “Chemo Dilemma” in ADAURA (2026 Update)
A key unanswered question from ADAURA: Should adjuvant cisplatin-based chemotherapy be given before or alongside osimertinib? In ADAURA, adjuvant chemotherapy was optional — about 60% of patients received it. The 2026 analysis suggests:
- Subgroup analyses do not clearly show additive benefit from adjuvant chemotherapy on top of osimertinib — but the trial was not powered for this comparison.
- Consensus in 2026: give adjuvant chemotherapy first (4 cycles), then start osimertinib — this mirrors the sequence tested in the trial and avoids concurrent toxicity.
- Do not give IO (PD-1/PD-L1) alongside or after osimertinib — excess interstitial lung disease risk, no benefit in EGFR+ disease.
ctDNA (MRD) Monitoring During Adjuvant Osimertinib
Molecular Residual Disease (MRD) via ctDNA: Prospective ctDNA monitoring during adjuvant osimertinib is now being studied as a surrogate for disease recurrence. Key principles:
- • Persistent ctDNA positivity post-resection (before adjuvant therapy) predicts a substantially higher risk of relapse vs ctDNA-negative patients.
- • Clearance of ctDNA during adjuvant osimertinib is associated with improved DFS in exploratory analyses of ADAURA.
- • Rising ctDNA on osimertinib may herald acquired resistance before clinical/radiological progression — but actionable thresholds are not yet defined in prospective guidelines.
- • Not yet standard of care — use within clinical trials where possible (e.g., MERMAID trials).
NeoADAURA: Neoadjuvant Osimertinib Data
NeoADAURA — Neoadjuvant Osimertinib in Resectable EGFR-Mutated NSCLC
Note: Low pCR reflects the biological mechanism of EGFR TKI — cytostatic rather than cytotoxic. MPR is a more relevant endpoint in this context.
Decision Framework: NeoADAURA vs ADAURA for Resectable EGFR+ Lung Cancer
| Scenario | Preferred Approach | Rationale |
|---|---|---|
| Stage IB–IIA, low nodal burden, resectable upfront | Upfront surgery → adjuvant osimertinib (ADAURA) | Proven OS benefit (HR 0.49); straightforward surgical access |
| Stage IIIA with bulky / multi-station N2 (N2b) | Neoadjuvant osimertinib ± chemo → surgery → adjuvant osimertinib | Neoadjuvant to downstage; NeoADAURA data supports feasibility |
| Stage IIIA N2a (single-station, small) | Either approach acceptable — MDT decision | Discuss surgical risk vs neoadjuvant downstaging benefit |
| Borderline resectable (lobectomy uncertain) | Neoadjuvant osimertinib + chemo → re-assess resectability | Combination achieves higher MPR; may convert to resectable |
MDT discussion essential in all EGFR+ resectable Stage IIIA disease.
Osimertinib Monotherapy vs Osimertinib + Chemo in Neoadjuvant Setting
Arguments for Osimertinib Monotherapy (Neoadjuvant)
- • Avoids chemotherapy toxicity (nausea, neuropathy, myelosuppression)
- • Good tolerability — patients can proceed to surgery in better functional state
- • Meaningful MPR rates achieved (~30%) without chemo
- • Preferred in patients unfit for chemotherapy
Arguments for Osimertinib + Chemotherapy (Neoadjuvant)
- • Higher MPR rates (≥50% in NeoADAURA) — more complete pathological response
- • Greater nodal downstaging — important for N2b disease
- • Addresses non-EGFR-driven tumor clones (chemotherapy covers heterogeneous subclones)
- • Preferred in high-volume N2 or multi-station N2 where downstaging is critical
Molecular Co-Mutations Favoring the Combination (Osimertinib + Chemo)
- TP53 co-mutation: Associated with reduced response to EGFR TKI monotherapy and inferior DFS. Combination with chemotherapy may partially overcome this resistance mechanism.
- High TMB (tumor mutational burden): Suggests clonal heterogeneity — chemotherapy better addresses non-EGFR clones.
- Amplification of MET or HER2: Potential bypass mechanisms. Consider combination to reduce residual disease burden.
- Complex EGFR mutations (exon 20 insertions, G719X, L861Q): Less osimertinib-sensitive — combination with chemotherapy is particularly preferred if surgery is the goal.
Biological Reasons for Low pCR in EGFR-Mutant Disease
Unlike IO-based regimens (CheckMate 816: 24% pCR), EGFR TKI therapy achieves low pCR rates (5–11%). The biological reasons are:
- 1. Cytostatic mechanism: Osimertinib inhibits EGFR signalling and induces cell cycle arrest rather than directly killing all tumor cells — residual viable cells persist on TKI even when tumor volume decreases.
- 2. Tumor heterogeneity: EGFR-mutant tumors often contain non-EGFR-driven subclones that are inherently TKI-resistant.
- 3. Stromal persistence: Fibrosis and stromal reaction may mask viable tumor cells on pathological assessment — apparent response may underestimate pathological residual.
- 4. Duration dependency: Longer neoadjuvant duration may increase pCR rates — optimal duration is not yet established in EGFR-mutant disease (3 cycles may be insufficient vs 6 months).
The Shift from pCR to MPR and Surgical Feasibility
Why MPR (Major Pathological Response) matters more than pCR in EGFR-mutant disease
ALK+ Resectable Stage II–III: ALINA, ELEVATE, and Neoadjuvant
Section ID: alk-resectable
ALK rearrangement confirmed — what is the evidence base for adjuvant and neoadjuvant therapy?
ALINA Trial: Adjuvant Alectinib
ALINA — DFS HR 0.24 vs platinum chemotherapy
Adjuvant alectinib for 2 years achieves a 76% reduction in the risk of disease recurrence or death compared to platinum-doublet chemotherapy in ALK-positive Stage IB–IIIA NSCLC. This is one of the most dramatic DFS improvements ever seen in an adjuvant lung cancer trial.
ALINA Trial — Full Data
Conclusion: Alectinib replaces chemotherapy as adjuvant therapy of choice for ALK-positive resected NSCLC.
ELEVATE Trial: Context
The ELEVATE trial examined ensartinib (a next-generation ALK TKI with CNS penetration) in the adjuvant setting for ALK-positive NSCLC. Though it demonstrated DFS benefit, the magnitude of benefit and CNS efficacy data were considered in comparison to ALINA in multidisciplinary discussions. Alectinib, with its established efficacy data and CNS penetration, remains the preferred adjuvant ALK TKI as of 2026.
The Comparison Gap — ALINA vs ELEVATE
Cross-trial comparisons are not head-to-head data
Neoadjuvant ALK TKI Options
Current status (2026): No Phase III randomised trial has established neoadjuvant ALK TKI as a standard pathway. Retrospective and single-arm data suggest:
- • Neoadjuvant alectinib or crizotinib can achieve tumor downstaging and facilitate R0 resection in borderline-resectable ALK+ cases.
- • MPR rates are low (similar to EGFR TKIs — cytostatic mechanism), but surgical feasibility may be improved.
- • Preferred approach in most centres: upfront surgery where possible → adjuvant alectinib (ALINA). Reserve neoadjuvant TKI for cases where surgery is not immediately feasible due to tumor extent.
- • Avoid neoadjuvant IO in ALK+ disease — extrapolating from EGFR+ data, IO is not beneficial and may cause excess immune-related toxicity.
ALK+ Resectable — MDT Planning Principles
Driver-Negative Resectable Stage II–III: Peri-operative Strategy
Section ID: driver-negative-resectable
EGFR/ALK negative — neoadjuvant, perioperative IO, or upfront surgery? How do you decide?
Arguments For and Against Neoadjuvant Therapy
Arguments FOR Neoadjuvant Therapy
- • Early treatment of micrometastatic disease
- • In vivo chemosensitivity assessment
- • Tumor downstaging — may convert to lobectomy from pneumonectomy
- • Nodal downstaging — N2 → N0 predicts long-term survival
- • pCR and MPR are validated surrogate endpoints (EFS correlation)
- • IO-based regimens dramatically increase pCR rates (24% with CheckMate 816)
- • Better surgical tolerance pre-operatively than post-operatively
Arguments AGAINST Neoadjuvant Therapy
- • Risk of disease progression during neoadjuvant treatment rendering patient inoperable
- • Delay to surgery (8–12 weeks) — psychological stress on patient
- • Toxicity may reduce surgical fitness
- • Post-IO surgery may have increased inflammation / adhesions
- • Stage migration — upstaging at surgery possible
- • In T3–4N0 disease, upfront surgery may be adequate
Neoadjuvant Therapy Response Assessment
After 3–4 cycles of neoadjuvant therapy, CT chest/abdomen/pelvis ± PET-CT is performed to assess response. Key response definitions:
Nodal Downstaging in NSCLC
Nodal downstaging (N2 → N0/N1) is one of the most powerful predictors of long-term survival in resected Stage IIIA NSCLC. Achieved in approximately 30–40% of cases with chemotherapy alone, and 45–60% with chemo-IO combinations. Patients who achieve ypN0 have 5-year OS rates of 50–60% vs 20–30% for those with persistent ypN2. Assessment requires systematic nodal sampling at thoracotomy — reliance on pre-operative re-staging PET alone is insufficient.
Decision on Neoadjuvant / Peri-operative Treatment
Preferred (EGFR/ALK wild-type, resectable Stage IIA–IIIA)
Peri-operative chemo-IO: neoadjuvant chemo + IO (3–4 cycles) → surgery → adjuvant IO 1 year. Supported by KEYNOTE-671, AEGEAN, CheckMate 77T.
Neoadjuvant-only (no adjuvant IO continuation)
CheckMate 816: nivolumab + chemo × 3 cycles → surgery (no adjuvant IO). FDA approved. Reasonable if adjuvant continuation is not feasible.
Upfront surgery → adjuvant therapy
Still appropriate for T3–4N0 (no N2 disease), smaller Stage IIA, or where neoadjuvant is contraindicated. Adjuvant chemo then IO (atezolizumab or pembrolizumab).
Neoadjuvant / Peri-operative Chemo-IO Options — Key Trials
CheckMate 816 — Nivolumab + Chemo (Neoadjuvant-only)
Key: Largest pCR improvement. First approved neoadjuvant IO regimen for NSCLC. Neoadjuvant-only design.
KEYNOTE-671 — Pembrolizumab + Chemo (Perioperative)
Key: Only regimen with significant OS benefit at this stage of follow-up. 1yr adjuvant pembro continuation.
AEGEAN — Durvalumab + Chemo (Perioperative)
Key: Extends to Stage IIIB. Includes adjuvant durvalumab continuation. EFS benefit confirmed.
CheckMate 77T — Nivolumab + Chemo (Perioperative)
Key: Highest numerical pCR among sandwich trials. Perioperative nivolumab regimen.
Perioperative IO Regimens — Full Comparison Table
Section ID: periop-io-table
How do the four perioperative IO regimens compare head-to-head across key endpoints?
No head-to-head RCTs exist between these regimens
| Parameter | CheckMate 816 | KEYNOTE-671 | AEGEAN | CheckMate 77T |
|---|---|---|---|---|
| Agent | Nivolumab | Pembrolizumab | Durvalumab | Nivolumab |
| Neoadjuvant cycles | 3 | 4 | 4 | 4 |
| Adjuvant IO | None | Pembro ×13 cycles (1yr) | Durva ×12 months | Nivo ×12 months |
| Stage eligible | IB–IIIA | II–IIIA | IIA–IIIB | IIA–IIIB |
| N (trial) | 358 | 797 | 802 | 461 |
| pCR (%) | 24.0 vs 2.2 | 18.1 vs 4.0 | 17.2 vs 4.3 | 25.3 vs 4.7 |
| MPR (%) | 36.9 vs 8.9 | 30.6 vs 11.0 | 33.3 vs 12.3 | 35.4 vs 12.1 |
| EFS HR | 0.63 | 0.59 | 0.68 | 0.58 |
| OS HR | 0.76 (NS) | 0.72 (significant) | 0.84 (immature) | Immature |
| OS benefit confirmed? | Not yet | Yes | Not yet | Not yet |
| R0 resection rate (IO arm) | 83.2% | 81.2% | 78.1% | ~80% |
| FDA approved? | Yes (2022) | Yes (2023) | Yes (2024) | Yes (2024) |
| Design | Neoadjuvant-only | Perioperative (sandwich) | Perioperative (sandwich) | Perioperative (sandwich) |
pCR = pathological complete response; MPR = major pathological response (≤10% viable tumor); EFS = event-free survival; NS = not statistically significant. Data from primary publications and ASCO 2024/2025 updates.
How to Choose Between Regimens
If you want neoadjuvant-only (no adjuvant IO commitment)
CheckMate 816 (nivolumab + chemo ×3 → surgery). Only validated neoadjuvant-only design.
If OS benefit is the primary driver
KEYNOTE-671 (pembrolizumab). Only regimen with significant OS benefit demonstrated at current follow-up.
If patient is Stage IIIB (borderline resectable)
AEGEAN or CheckMate 77T — enrolled IIIB patients; CheckMate 816/671 limited to IIIA.
If local reimbursement favors one agent
Follow local formulary — all four are guideline-supported.
If EGFR/ALK positive
None of the above — avoid all IO. See EGFR+ and ALK+ sections.
The Neo-MEMORY Project — Neoadjuvant Determinants
The Neo-MEMORY project (Determinants of Long-Term Benefit Upon Neoadjuvant Treatments in Resectable NSCLC in the Era of Immunotherapy) is an ongoing academic initiative pooling individual patient data from neoadjuvant NSCLC trials to identify: (1) biomarkers of long-term benefit from neoadjuvant IO (TMB, PD-L1 TPS, STK11, KEAP1); (2) the relative importance of pCR vs MPR vs nodal downstaging as endpoints; (3) the impact of adjuvant IO continuation on outcomes in patients with residual disease post-surgery.
Surgery as an Inflammatory Boost for irPneumonitis
Post-neoadjuvant IO surgery and immune-related pneumonitis risk
Resectable Stage IIIA: Non-Bulky N2 — Treatment Strategy Summary
Section ID: resectable-iiia
Multidisciplinary review agrees this is technically resectable — what's the treatment strategy?
Acceptable Treatment Strategies (No Single Universal SOC)
Neoadjuvant chemo-IO (CheckMate 816, KEYNOTE-671, AEGEAN, or CheckMate 77T) → surgery → adjuvant IO (1 year, except CheckMate 816).
Upfront surgery → adjuvant cisplatin-based chemotherapy → adjuvant IO or targeted therapy (based on biomarker profile).
Neoadjuvant concurrent CRT → surgery. Superseded by chemo-IO data in most centres.
EGFR/ALK+ Resectable Stage IIIA
Avoid IO. Preferred approach: neoadjuvant chemotherapy alone → surgery → adjuvant targeted therapy (osimertinib for EGFR [ADAURA], alectinib for ALK [ALINA]).
Surgical Considerations (INT 0139)
- INT 0139: CRT (45Gy cisplatin/etoposide) → surgery vs CRT alone (61Gy). PFS improved with surgery (12.8 vs 10.5 mo). OS not significant overall (23.6 vs 22.2 mo).
- Lobectomy subgroup showed OS benefit; pneumonectomy associated with increased TRM (8% vs 2%) — avoid pneumonectomy after CRT.
- Surgery in Stage IIIA only for highly selected patients where lobectomy is feasible.
- Superior sulcus (Pancoast) tumors: induction CRT → surgery → consolidation chemotherapy (see Section 14).
INT 0139 — CRT + Surgery vs Definitive CRT
Conclusion: surgery reserved for cases where lobectomy is feasible; pneumonectomy after CRT should be avoided.
Unresectable Stage III NSCLC: The Stage III Challenge
Section ID: unresectable
MDT has determined this is unresectable — what is the standard pathway and what defines N2 resectability?
The Stage III Challenge
Stage III NSCLC encompasses an extraordinarily heterogeneous group: from single-station N2a (now Stage IIB in 9th edition) potentially resectable with curative intent, to bulky N3 disease with contralateral mediastinal involvement that is firmly in the unresectable category. The central challenge is correctly stratifying patients along the resectable / borderline resectable / unresectable spectrum — a decision that must be made by a multidisciplinary team including thoracic surgery, radiation oncology, and medical oncology.
N2 Resectability Criteria
| N2 Category | 9th Ed Stage | Resectability | Preferred Approach |
|---|---|---|---|
| N2a — single station, small node (≤1.5cm on CT) | IIB–IIIA | Potentially resectable | Neoadjuvant chemo-IO → surgery → adjuvant IO |
| N2a — single station, bulky node (≥1.5cm on CT) | IIIA | Borderline resectable — MDT | Neoadjuvant chemo-IO → re-assess. If downsized → surgery. Else → definitive CRT |
| N2b — multi-station N2 | IIIB | Generally unresectable | Definitive CRT → durvalumab consolidation |
| N3 — contralateral mediastinal / supraclavicular | IIIC | Unresectable | Definitive CRT → durvalumab. Rarely oligometastatic SBRT |
Radical Options for Stage III Disease
- Resectable: Neoadjuvant chemo-IO → surgery (lobectomy / pneumonectomy) → adjuvant IO / targeted therapy
- Borderline resectable: Neoadjuvant therapy to downstage → re-assess with CT ± PET → proceed to surgery or definitive CRT based on response
- Unresectable but ECOG 0–2: Definitive concurrent CRT (60Gy + cisplatin/etoposide or carboplatin/paclitaxel) → consolidation IO (durvalumab or osimertinib if EGFR+)
- Unresectable, poor performance (PS 3–4): RT alone (palliation), best supportive care, or sequential CRT if borderline fitness
Standard of Care: Concurrent Chemoradiation Therapy (cCRT)
- • cCRT superior to sequential chemo → RT (sCRT) in overall survival — cCRT preferred
- • Sequential CRT: acceptable for patients unfit for concurrent (PS 2, significant comorbidity, poor pulmonary reserve)
- • RT alone: only if patient is unfit for any chemotherapy
Concurrent CRT (cCRT) vs Sequential CRT (sCRT)
| Parameter | Concurrent CRT (cCRT) | Sequential CRT (sCRT) |
|---|---|---|
| OS | Superior (~16–17 months median) | Inferior (~13–14 months median) |
| Local control | Better | Less effective |
| Esophagitis | Higher (Grade 3–4 ~20–30%) | Lower |
| Myelosuppression | Higher | Lower |
| Patient fitness required | ECOG 0–1, adequate pulmonary reserve | ECOG 0–2, more comorbidities tolerated |
| Preferred? | Yes — standard of care | Reserve for cCRT-ineligible only |
cCRT = concurrent chemoradiation; sCRT = sequential chemoradiotherapy.
Chemotherapy Regimen and RT Dose for cCRT / sCRT
Preferred Chemotherapy Regimens
| Regimen | Setting | Key Data | Comment |
|---|---|---|---|
| Cisplatin 50mg/m² days 1, 8, 29, 36 + Etoposide 50mg/m² days 1–5, 29–33 | cCRT (preferred) | 5yr OS ~15%; Grade 3–4 esophagitis ~20% | Gold standard for cisplatin-eligible patients; most evidence base |
| Cisplatin 75mg/m² d1 + Vinorelbine 25mg/m² d1,8 q3w | cCRT (alternative) | Used in PACIFIC trial population | Acceptable alternative; common outside North America |
| Cisplatin 75mg/m² d1 + Pemetrexed 500mg/m² d1 q3w (non-squamous) | cCRT (alternative) | PROCLAIM: no OS benefit vs cis/etop (26.8 vs 25 months) | Not preferred over standard regimen; consider in frail or elderly non-squamous |
| Carboplatin AUC2 + Paclitaxel 45–50mg/m² weekly | cCRT (cisplatin-ineligible) | 3yr OS 26% vs 41.1% with cis/etop; lower toxicity | Reserve for cisplatin-ineligible; lower efficacy |
| Carboplatin AUC5 + Paclitaxel 200mg/m² q3w (induction + consolidation) | sCRT | Used historically; lower esophagitis than cCRT | Acceptable for sCRT; consider for PS 2 or significant comorbidity |
RT dose for all regimens: 60Gy in 30 fractions of 2Gy/day (see below). PROCLAIM = PROCLAIM trial (JCO 2016).
Radiotherapy — Technology, Dose, and the Failure of Escalation
Section ID: rt-technology
What RT dose is standard, why did escalation fail, and what modern technologies improve outcomes?
The Standard Dose and the Failure of Escalation
RTOG 0617 — 60Gy Standard, Dose Escalation to 74Gy Harmful
RTOG 0617 (N=544) randomised patients to 60Gy vs 74Gy (standard vs high dose) with concurrent carboplatin/paclitaxel. Counter-intuitively, the high-dose arm (74Gy) had inferior OS (20.3 vs 28.7 months, HR 1.38 for death with 74Gy). The mechanism is thought to involve greater cardiopulmonary toxicity at 74Gy, including higher rates of Grade ≥3 esophagitis, pneumonitis, and cardiac exposure. Dose escalation above 60Gy is contraindicated and should not be used.
- Standard RT dose: 60Gy in 30 daily fractions of 2Gy — the validated, safe standard
- Twice-daily (hyperfractionated) RT: 45Gy in 1.5Gy BID fractions — alternative for selected limited-stage, good-performance patients; avoids prolonged overall treatment time
- 74Gy is contraindicated — worse OS and higher cardiopulmonary toxicity (RTOG 0617)
- CHART (Continuous Hyperfractionated Accelerated Radiotherapy): 54Gy in 36 fractions over 12 days — used in some European centres for Stage III NSCLC. Requires twice-daily treatment including weekends.
Technological Advances in RT
4D-CT and Respiratory Gating
Accounts for respiratory motion during planning and delivery. Reduces internal target volume (ITV) expansions needed. Standard in modern thoracic RT planning.
IMRT / VMAT (Volumetric Arc Therapy)
Highly conformal dose delivery. Reduces dose to heart, lung, esophagus vs 3D-CRT. Mandatory at centres treating unresectable Stage III — cardiac dose reduction may underlie OS improvement in PACIFIC era.
Proton Beam Therapy (PBT)
No exit dose (Bragg peak). Reduces mean lung dose and cardiac dose significantly. Preferred for: central tumors near esophagus/heart, compromised pulmonary function, bilateral nodal coverage. Access remains limited.
PET-guided RT Planning
FDG-PET integrated into RT planning to identify metabolically active nodal disease. Reduces geographic miss and unnecessary nodal irradiation (elective nodal irradiation increasingly omitted in favour of involved-field RT).
Adaptive RT
Mid-treatment replanning based on tumor shrinkage. Allows safer dose delivery as tumor regresses during CRT. Not yet standard but increasingly used at academic centres.
Stereotactic Body RT (SBRT)
Not standard for Stage III but may be used for oligoprogressive or oligometastatic sites in the context of consolidation therapy. High doses per fraction (e.g., 50Gy in 5 fractions).
RTOG 0617 — Full Data (Dose Escalation Failure)
Conclusion: 74Gy dose escalation is harmful, not beneficial. 60Gy remains the standard.
Durvalumab Consolidation After CRT (PACIFIC)
Section ID: pacific
CRT is done with no progression — durvalumab is now standard. For whom and for how long?
Consolidation Durvalumab — PD-L1 Expression Requirements
PD-L1 and durvalumab eligibility (2026 position): The original PACIFIC trial enrolled patients irrespective of PD-L1 status. Updated PACIFIC analyses and subsequent exploratory data showed:
- • PD-L1 ≥1%: Clear OS and PFS benefit from durvalumab consolidation.
- • PD-L1 <1%: Benefit is less certain. OS HR favors durvalumab but CIs cross 1.0 in PD-L1 <1% subgroup (HR ~1.14 in some analyses).
- • Current NCCN / ESMO position (2026): Durvalumab is recommended regardless of PD-L1 in most guidelines — do not withhold based on PD-L1 alone. However, in PD-L1 <1%, MDT discussion is appropriate, particularly for patients at high risk of immune-related pneumonitis.
- • PD-L1 testing before consolidation decision is still recommended for informational and prognostic purposes.
Consolidation Durvalumab — EGFR/ALK/Driver Status Impact
| Driver Status | Durvalumab Indicated? | Alternative | Evidence |
|---|---|---|---|
| EGFR wild-type, ALK-negative | Yes — standard of care | — | PACIFIC trial — OS HR 0.72, 5yr OS 42.9% vs 33.4% |
| EGFR Ex19del / L858R | No — avoid durvalumab | Osimertinib 80mg/day (LAURA trial) | LAURA: PFS 39.1 vs 5.6 months (HR 0.16) |
| ALK-rearranged | No — avoid durvalumab | Alectinib consolidation (MDT, extrapolation) | No prospective RCT — ALINA data extrapolated; avoid IO |
| ROS1 / RET / MET ex14 | No proven benefit | MDT discussion — relevant TKI if available | No prospective data for consolidation TKI in unresectable Stage III |
| KRAS G12C | Yes (if no contraindication) | — | KRAS G12C is not a contraindication to IO. Sotorasib/adagrasib are not established in consolidation. |
| Other/unknown | Yes — follow PACIFIC algorithm | — | Assume IO-eligible unless specific driver contraindication identified |
EGFR/ALK testing mandatory before any consolidation decision in unresectable Stage III NSCLC.
Eligibility and Dosing
- Unresectable Stage III NSCLC — completed concurrent CRT, PS 0–1, no progression
- Timing: start durvalumab within 1–42 days after last RT fraction
- Dose: durvalumab 10mg/kg q2w (or 1500mg q4w flat dose) × 12 months
- PD-L1 status: durvalumab is recommended irrespective of PD-L1 — benefit shown regardless of PD-L1 in updated PACIFIC analyses (see above)
PACIFIC Trial — Full Data
Conclusion: Durvalumab consolidation after CRT = global standard of care for unresectable Stage III (EGFR/ALK wild-type or unknown).
Key Exclusions and Cautions
- Active autoimmune disease → use durvalumab with caution or avoid; assess risk-benefit individually
- Grade ≥2 pneumonitis from CRT → hold durvalumab until resolution to Grade ≤1
- EGFR-mutated or ALK-rearranged: do NOT use durvalumab — use targeted consolidation instead (see Section 13 below)
EGFR-Mutated Unresectable Stage III — Osimertinib After CRT (LAURA)
Section ID: laura
EGFR Ex19del or L858R — osimertinib replaces durvalumab after CRT. What's the data?
LAURA Trial — PFS: 39.1 vs 5.6 months (HR 0.16)
Dramatic benefit of osimertinib consolidation in EGFR-mutated (Ex19del or L858R) unresectable Stage III NSCLC after CRT. FDA approved 2024 — new standard of care.
LAURA Trial — Full Data (ASCO 2023 / NEJM 2024)
Key Clinical Points
- Do NOT use durvalumab in EGFR-mutated Stage III — no proven benefit, potential for excess immune toxicity.
- EGFR mutation testing is therefore mandatory before any consolidation decision in unresectable Stage III NSCLC.
- ALK-rearranged unresectable Stage III: no specific prospective data; avoid IO; consider alectinib consolidation (extrapolation from ALINA trial in resected ALK+). Not yet established standard — discuss in MDT.
- Other drivers (ROS1, RET, MET): no specific consolidation trial data; manage empirically with MDT discussion.
- The PFS benefit of osimertinib in LAURA (HR 0.16 — 84% risk reduction) is the largest consolidation IO/TKI benefit ever demonstrated in Stage III NSCLC. It likely reflects both the anti-tumour TKI effect and prevention of CNS micrometastases.
Superior Sulcus / Pancoast Tumors
Section ID: pancoast
T3–T4 apical tumor invading chest wall — how does Pancoast management differ?
Standard Approach — Resectable Pancoast
- Induction CRT: cisplatin/etoposide + RT (45Gy) → surgery (en bloc resection) → consolidation chemotherapy
- Requires experienced thoracic surgical team; may involve thoracic outlet structures, subclavian vessels, brachial plexus
SWOG 9416 / INT 0160 — Pancoast Induction CRT Data
Demonstrates meaningful survival with trimodality approach. R0 resection is the critical determinant of outcome.
Unresectable Pancoast
- Treat with definitive CRT (60Gy) + durvalumab consolidation — apply PACIFIC eligibility criteria
Horner's Syndrome
Ptosis, miosis, anhidrosis — suggests invasion of the sympathetic chain (stellate ganglion). Does not preclude surgery but indicates complex resection will be required. Plan for extensive en bloc resection; discuss at specialist MDT.
Clinical FAQs
1Can durvalumab be used in EGFR-mutated Stage III NSCLC?
2What if the patient progresses during CRT — can they still get durvalumab?
3Is PORT (postoperative radiotherapy) ever indicated after complete resection of Stage III NSCLC?
4Which perioperative IO regimen is preferred for resectable Stage IIIA NSCLC?
5How soon after CRT should durvalumab start?
6What is the optimal radiation dose for unresectable Stage III NSCLC?
7What is the OS benefit from adjuvant osimertinib in ADAURA?
8What is STAS and why does it matter in surgical planning?
9Can IO be used perioperatively in EGFR-mutated NSCLC?
Is 3 Years of Adjuvant Osimertinib Enough?
Section ID: osimertinib-duration
The ADAURA trial mandated 3 years — but is that the biologically optimal duration? What happens after stopping?
In ADAURA, osimertinib was given for a fixed 3 years (or until recurrence / unacceptable toxicity). The rationale for 3 years was pragmatic — based on DFS curves and resource considerations — rather than biologically derived from a dose-duration study. Three key questions remain open:
1. Recurrence After Stopping Osimertinib
After stopping osimertinib at 3 years, disease recurrence can occur — including EGFR-sensitising recurrences (re-emergence of the original EGFR-mutant clone after TKI withdrawal) and acquired-resistance recurrences (T790M, C797S, MET amplification). In ADAURA exploratory analyses, DFS curves continue to separate beyond 3 years, but the post-treatment recurrence rate accelerates after drug discontinuation in a subset of patients. The OS benefit (HR 0.49) at the time of data maturity partially reflects this pattern.
2. Extended Osimertinib Beyond 3 Years — Evidence Gap
- No prospective randomised trial has evaluated extended (beyond 3 years) vs fixed 3-year adjuvant osimertinib. Continuation beyond 3 years is not a formal guideline recommendation as of 2026.
- Observational and compassionate-use data suggest some clinicians continue osimertinib beyond 3 years in patients at high recurrence risk (pN2, positive margins, multiple high-risk features) — but this is practice variation, not evidence-based guidance.
- In the LAURA trial (unresectable Stage III), osimertinib is continued until progression — no fixed duration. This contrasts with the ADAURA adjuvant design and raises the biological question of whether indefinite TKI continuation in a curative-intent setting might improve outcomes.
- The ongoing ADAURA2 trial (in concept) and extended osimertinib sub-studies may address this question prospectively. Until data matures, 3 years remains the standard.
3. ctDNA (MRD) as a Guide to Duration
A compelling emerging hypothesis: ctDNA negativity at 3 years may be a signal that drug can be safely stopped, while ctDNA positivity may justify continuation. Several ongoing MRD-guided trials are testing this paradigm. Key considerations:
- • Patients who are ctDNA-negative at 3 years are likely at low risk of immediate recurrence and may be candidates for treatment discontinuation.
- • Patients who remain ctDNA-positive despite 3 years of osimertinib may benefit from continuation or treatment escalation (e.g., osimertinib + amivantamab in trials).
- • ctDNA-guided duration decisions are not yet validated prospectively and should only be applied within clinical trials or after extensive MDT discussion.
4. Toxicity Considerations for Extended Duration
- Osimertinib is well-tolerated long-term — Grade ≥3 AEs are uncommon (<10% in ADAURA). Diarrhea, paronychia, and interstitial lung disease (ILD) are the main concerns.
- ILD risk: approximately 3–4% cumulative in ADAURA. ILD is the most serious toxicity and requires immediate drug hold and corticosteroid therapy. QTc prolongation is a secondary cardiac concern with long-term use — periodic ECG monitoring is recommended.
- The favourable toxicity profile of osimertinib makes longer treatment durations theoretically feasible from a tolerability standpoint — the limiting factor is evidence, not toxicity.
Current 2026 Position
Adjuvant osimertinib for 3 years per ADAURA is the standard. Do not extend beyond 3 years outside clinical trials. At completion, monitor with CT every 6 months for 2 years then annually. Restart osimertinib at progression if sensitising EGFR mutation is still present (re-biopsy if feasible). If acquired T790M resistance at relapse: switch to a 3rd-gen approach; if C797S or other tertiary resistance: enrol in clinical trial.
IASLC 9th Edition TNM Staging: Clinical Implications for Stage II–III
Section ID: iaslc-9th-staging
The 9th edition changed which N2 substage maps to Stage IIB vs IIIA — how does this affect management decisions?
Key 9th Edition Change: N2 Subdivision
The IASLC 9th Edition (published 2024, implemented 2026) introduces a critical subdivision of N2 into N2a (single-station ipsilateral mediastinal) and N2b(multi-station ipsilateral mediastinal). This is clinically significant because N2a is now downstaged relative to the 8th Edition, reflecting the improved survival outcomes achievable with modern multimodality treatment in single-station N2 disease.
Critical Stage Group Changes (8th → 9th Edition)
| T/N Descriptor | 8th Edition Stage | 9th Edition Stage | Clinical Impact |
|---|---|---|---|
| T1N1 | Stage IIB | Stage IIA | Downstaged — lower risk category; affects adjuvant chemo threshold |
| T1N2a (single-station N2) | Stage IIIA | Stage IIB | Significant downstage — now potentially approaches resectable Stage II thresholds |
| T2N2a | Stage IIIA | Stage IIIA | Unchanged — but N2a designation clarifies single-station nature |
| T3N2a | Stage IIIA | Stage IIIA | Unchanged |
| T2N2b (multi-station N2) | Stage IIIA | Stage IIIB | Upstaged — multi-station N2 now IIIB; generally unresectable → CRT + consolidation |
| T4N2b | Stage IIIB | Stage IIIC | Upstaged |
| M1c (any multi-organ) | Stage IVB | M1c1 (single organ) / M1c2 (multi-organ) — both IVB | Prognostic subdivision — M1c2 worse prognosis |
9th Edition implemented 2026. Source: IASLC Staging Manual 9th Ed, Detterbeck et al.
N2a vs N2b — Why It Matters for Management
N2a (Single-Station)
- • Now Stage IIB (if T1) or IIIA (if T2–T3)
- • Potentially resectable — MDT assessment required
- • Amenable to neoadjuvant chemo-IO → surgery
- • Nodal downstaging to N0/N1 predicts excellent long-term outcomes
- • EBUS biopsy essential to confirm truly single-station involvement
N2b (Multi-Station)
- • Now Stage IIIB — generally unresectable
- • Definitive concurrent CRT is the primary curative approach
- • Consolidation durvalumab (or osimertinib if EGFR+) after CRT
- • Surgery only in highly selected cases after dramatic downstaging
- • Multi-station involvement confirmed by EBUS/EUS mapping of each station
EBUS/EUS Mediastinal Staging — Required Before Classification
The clinical distinction between N2a and N2b requires pathologic confirmation, not just radiological assessment. CT and PET-CT alone cannot reliably distinguish single-station from multi-station involvement — up to 25% of clinically N2 cases on CT are N2b (multi-station) when systematically biopsied by EBUS. Systematic EBUS ± EUS-FNA of all suspicious stations is mandatory before classifying a patient as resectable N2a vs unresectable N2b.
Station 4R
Right lower paratracheal
Station 4L
Left lower paratracheal
Station 7
Subcarinal
Station 2R/2L
Upper paratracheal
Station 10
Hilar (EBUS-reachable)
Station 8/9
Para-oesophageal / Ligament (EUS preferred)
Mock Viva: 9th Edition Staging Cases
Q1.A 62-year-old male has a 2.5cm upper lobe mass and a single 1.2cm station 4R node positive on EBUS. No distant spread. Stage?
Q2.A patient has a 3.5cm tumor and biopsy-proven involvement of stations 4R and 7. Stage?
Q3.Patient has multiple liver metastases (3 lesions) and 2 bone metastases. M classification in 9th Edition?
Stage III NSCLC: Clinical Decision Algorithm
Section ID: decision-algorithm
New diagnosis of Stage III NSCLC confirmed — walk through the decision pathway step by step.
Step 1 — Confirm Staging
CT chest/abdomen/pelvis + PET-CT + Brain MRI. If nodes suspicious on CT/PET → EBUS ± EUS to confirm N2a vs N2b (mandatory pathologic staging of mediastinum).
Step 2 — Molecular Testing
Comprehensive molecular profiling: EGFR (Ex19del, L858R, exon 20, G719X, L861Q), ALK, ROS1, KRAS G12C, MET ex14, RET, NTRK. PD-L1 TPS. This changes consolidation strategy entirely.
Step 3 — Resectability MDT Assessment
Thoracic surgery + radiation oncology + medical oncology. Key question: Is the patient resectable for lobectomy (not pneumonectomy)? Pneumonectomy after neoadjuvant therapy carries high TRM (8% in INT 0139).
Branch A — Resectable (Lobectomy Feasible)
A1 — EGFR-mutated (Ex19del / L858R)
Options: (a) Upfront surgery → adjuvant osimertinib 3yr [ADAURA]. Or (b) Neoadjuvant osimertinib ± chemo → surgery → adjuvant osimertinib [NeoADAURA]. MDT decision based on nodal burden and surgical risk. Do NOT use IO.
A2 — ALK-rearranged
Surgery → adjuvant alectinib 2yr [ALINA]. Neoadjuvant ALK TKI for borderline resectable (MDT, no RCT data). Do NOT use IO.
A3 — EGFR/ALK wild-type (Driver-negative)
Preferred: Neoadjuvant chemo-IO × 3–4 cycles → surgery → adjuvant IO × 1yr [KEYNOTE-671, AEGEAN, CheckMate 77T]. Alternative (neoadjuvant-only): CheckMate 816. After surgery, continue adjuvant IO per regimen.
Branch B — Unresectable (N2b, N3, or Technical Contraindication)
B1 — EGFR-mutated (Ex19del / L858R)
Concurrent CRT (60Gy + cisplatin-based, or carbo/paclitaxel if cisplatin-ineligible) → osimertinib 80mg/day until progression [LAURA — PFS HR 0.16]. Do NOT use durvalumab.
B2 — EGFR/ALK wild-type
Concurrent CRT (60Gy + cisplatin-etoposide or carbo/paclitaxel) → durvalumab 1500mg q4w × 12 months [PACIFIC — 5yr OS 42.9% vs 33.4%]. PD-L1 not required but check for prognostic purposes.
B3 — PS 2 or cisplatin-ineligible
Sequential CRT (carboplatin/paclitaxel → RT 60Gy) → durvalumab if no progression. Or RT alone if chemotherapy contraindicated. Involve palliative care early.
B4 — PS 3–4 or extensive comorbidity
Palliative intent RT (for symptom control) ± best supportive care. Referral to palliative care team. Clinical trial enrolment where available.
Step 4 — Surveillance After Curative-Intent Treatment
Post-surgical surveillance
- • CT chest ± abdomen every 6 months × 2 years
- • Then annually × 3 years
- • History/exam every 3–6 months × 2yr then annually
Post-CRT + consolidation surveillance
- • CT chest/abdomen every 6 months during durvalumab/osimertinib
- • After consolidation completion: CT every 6–12 months
- • Brain MRI at progression or symptom onset
High-Yield Oral Exam Summary — Stage II–III NSCLC
Section ID: exam-summary
How would you summarise Stage II–III NSCLC management in a viva or MDT presentation?
Oral Script — Stage III NSCLC
“When managing Stage III NSCLC, my first priority is multidisciplinary assessment to distinguish resectable from unresectable disease, using the 9th Edition TNM classification to distinguish N2a (single-station) from N2b (multi-station) nodal involvement. I require pathologic mediastinal staging by EBUS ± EUS before any treatment decision.
For resectable, EGFR-wild-type disease: I prefer perioperative chemo-IO — neoadjuvant nivolumab/pembrolizumab/durvalumab plus chemotherapy followed by surgery, then adjuvant IO continuation (KEYNOTE-671, AEGEAN, CheckMate 77T). Neoadjuvant-only CheckMate 816 is an alternative.
For EGFR-mutated resectable disease: I use adjuvant osimertinib per ADAURA (OS HR 0.49), or neoadjuvant osimertinib ± chemotherapy followed by adjuvant osimertinib for bulky N2b disease (NeoADAURA). I avoid IO entirely in EGFR+ and ALK+ disease.
For ALK-rearranged resectable disease: adjuvant alectinib per ALINA (DFS HR 0.24).
For unresectable Stage III EGFR-wild-type: definitive concurrent CRT (60Gy, cisplatin-etoposide) followed by consolidation durvalumab 12 months (PACIFIC — 5yr OS 42.9%). For unresectable EGFR-mutated disease: concurrent CRT then consolidation osimertinib until progression (LAURA — PFS HR 0.16, median PFS 39.1 vs 5.6 months).
I would not use PORT after complete R0 resection — Lung-ART showed no OS benefit and increased cardiopulmonary toxicity. PORT is reserved for R1–R2 resection only.”
One-Line Trial Summaries
These guidelines are intended for qualified healthcare professionals. Content reflects NCCN NSCLC 3.2025, ESMO guidelines 2026, and IASLC 9th Edition TNM Classification. Clinical judgement and local multidisciplinary team discussion should guide individual patient management. OncoToolkit does not replace formal medical advice.